GU Cancers 2024 | The emerging benefits of adjuvant checkpoint inhibition in RCC

David Braun, MD, PhD, Yale School of Medicine, New Haven, CT, comments on the role of adjuvant checkpoint inhibitors for patients with renal cell carcinoma (RCC). Findings from the Phase III KEYNOTE-564 trial (NCT03142334) demonstrated the benefits of adjuvant pembrolizumab in terms of disease-free survival and overall survival, especially in patients with high risk disease. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.